Although respiratory syncytial virus (RSV) doesn’t lead to severe symptoms in adults and older children, it can manifest in the form of a threatening infection among babies, especially those placed in high-risk groups. In adults with a compromised immune system, however, RSV can cause severe respiratory infections. In a new report that is now available on MarketResearchReports.biz, the scope of the market’s growth is discussed in detail. The report, titled “EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast To 2024,” provides a complete overview of the various risk factors contributing to the growth of the market, the comorbidities, and the emerging RSV trends globally.
Identified as one of the most common causes of respiratory infections among the pediatric population, it is estimated that virtually all children are infected by this virus at least once till the time they reach the age of two years. However, it’s not just children that contract this virus. The report states that RSV also causes respiratory illnesses even among adults. However, the virus isn’t considered a severe threat because the majority of such infections self-resolve within approximately two weeks of the person being infected by it. However, about 1% of all cases can progress into very severe lower respiratory complications and require the patient to be hospitalized for treatment.
Given its attribute of being easily transmissible, especially in nursing homes, RSV is associated with a significant mortality and morbidity rate. Those in the high-risk group are administered prophylactic treatment.
The study focuses on the seven major markets (MM), which are: France, the U.S., Germany, Spain, Italy, Japan and UK. A 10-year epidemiological forecast forms the highlight of the report. This particular forecast is focused on the number of infants hospitalized for an RSV infection. Furthermore, the report also studies and forecasts the adult and pediatric populations that face the highest risk of contracting an RSV infection, and are thus likely to be administered prophylactic treatment. The population eligible for such a treatment – the prophylactic population – is further studied in detail in the report.
What sets this report apart from other similar studies is that it has been authored by a team of highly experienced and qualified epidemiologists. Thanks to these attributes, this EpiCast report stands as an authoritative study of the current scenario of the respiratory syncytial virus (RSV) infection market.
In order to conduct an in-depth study of the prevalence of respiratory syncytial virus (RSV) infections, the authors segment the population groups studied in the report based on age and sex. This enables them to offer an even more granular overview of the number of types of patients hospitalized owing to RSV and are receiving prophylactic treatment in the seven major markets. Moreover, the forecast presented in the study draws from a myriad of factors such as population trends, number of births, preterm births, the rate of infant mortality, incidence and prevalence of the disease, and mortality rate. The report is composed of 14 tables and five figures.
To order report Call Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org